For GILD share holders or anyone of interest# Stock
f*y
1 楼
This is the news on Oct 10th, 2014 (FRIDAY) when Harvoni is approved. What
you want to keep an eye on is how ABBV's drug will be priced compare to
gilead's $94,500.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
++
http://www.nytimes.com/2014/10/11/business/harvoni-a-hepatitis-
The first complete treatment for hepatitis C that requires taking only a
once-a-day pill won approval Friday from the Food and Drug Administration.
The drug, called Harvoni from Gilead Sciences, could shorten the duration of
treatment and provide the first all-oral regimen for many patients.
The new drug also appears to be a bit less expensive for some patients than
Gilead’s existing blockbuster hepatitis C drug, Sovaldi, which has become
the poster child for those complaining that the cost of medicines is out of
control.
Sovaldi costs $1,000 a pill, or $84,000 for a typical 12-week course of
treatment, but it must be used with other drugs. Harvoni is even more
expensive at $1,125 a pill, or $94,500 for a 12-week course of treatment.
But that is roughly in line with the total cost for Sovaldi and the drugs
used with it. Many patients will be able to take Harvoni for only eight
weeks, at a cost of about $63,000.
This will probably not mollify insurance companies and Medicaid programs,
many of which are restricting the use of Sovaldi to the most seriously ill
patients.
you want to keep an eye on is how ABBV's drug will be priced compare to
gilead's $94,500.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
++
http://www.nytimes.com/2014/10/11/business/harvoni-a-hepatitis-
The first complete treatment for hepatitis C that requires taking only a
once-a-day pill won approval Friday from the Food and Drug Administration.
The drug, called Harvoni from Gilead Sciences, could shorten the duration of
treatment and provide the first all-oral regimen for many patients.
The new drug also appears to be a bit less expensive for some patients than
Gilead’s existing blockbuster hepatitis C drug, Sovaldi, which has become
the poster child for those complaining that the cost of medicines is out of
control.
Sovaldi costs $1,000 a pill, or $84,000 for a typical 12-week course of
treatment, but it must be used with other drugs. Harvoni is even more
expensive at $1,125 a pill, or $94,500 for a 12-week course of treatment.
But that is roughly in line with the total cost for Sovaldi and the drugs
used with it. Many patients will be able to take Harvoni for only eight
weeks, at a cost of about $63,000.
This will probably not mollify insurance companies and Medicaid programs,
many of which are restricting the use of Sovaldi to the most seriously ill
patients.
